Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 13

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 13
---
 issuance of our common stock and entered
into an At The Market Offering Agreement (the “ATM Agreement”) with Rodman & Renshaw LLC under which the Company may
offer and sell shares of its Common Stock, with an aggregate offering amount sold of up to $100,000,000. During the nine months ended
September 30, 2025, the Company sold a total of 2,668,300 shares of its common stock, at a weighted average price of $2.17 for total
proceeds of $5,550,008, net of costs of $230,292.

Restricted
Stock Units

On
May 27, 2025, 400,000 fully vested common shares were granted for services to the Company’s CEO. The restricted shares were valued
at $840,000 based on the stock quoted trading price at the grant date and were expensed immediately as compensation expense.

    10

Warrants

In
connection with various transactions and the IPO summarized below, the Company issued stock warrants. Warrant activity for the nine months
ended September 30, 2025 and 2024 is summarized below:

 Schedule
of warrant activity

    Weighted  

    Weighted  
    Average  

    Average  
    Remaining  
    Aggregate 

    Number of  
    Exercise  
    Contractual  
    Intrinsic 

    Warrants  
    Price  
    Term (Years)  
    Value 
  
    Outstanding as December 31, 2023 
     2,774,057  
    $4.85  
     4.5(1) 
     - 
  
    Granted 
     50,000  
    $7  
     4.1  
     - 
  
    Outstanding as September 30, 2024 
     2,824,057  
    $4.89  
     4.25  
     - 

    Outstanding as December 31, 2024 
     2,814,057  
    $4.97  
     3.49(2) 
     - 
  
    Granted 
     -  
    $-  
     -  
     - 
  
    Outstanding as of September 30, 2025 
     2,814,057  
    $4.97